Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …

Background Multiple sclerosis (MS) is a chronic and autoimmune disease of the central
nervous system (CNS), mainly characterized by inflammatory demyelination, which …

Multiple sclerosis (MS) is a chronic inflammatory condition of the central nervous system
determined by a presumed autoimmune process mainly directed against myelin …

This paper provides a thorough overview of the current advances in diagnosis and therapy
of myasthenia gravis (MG). Nowadays the term 'myasthenia gravis' includes heterogeneous …

Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading
to disability in young adults. The outcome of the disease is unpredictable, and over time …

Lysophospholipids (LPs), including lysophosphatidic acid (LPA), sphingosine 1-phospate
(S1P), lysophosphatidylinositol (LPI), and lysophosphatidylserine (LysoPS), are bioactive …

In recent years, there has been a paradigm shift in the treatment of multiple sclerosis (MS)
owing to the approval of a number of new drugs with very distinct mechanisms of action. All …

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In
recent years, many disease-modifying therapies (DMT) have been approved for MS …

Multiple sclerosis (MS) has a longitudinal and heterogeneous course, with an increasing
number of therapy options and associated risk profiles, leading to a constant increase in the …

Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to
steroids (CLIPPERS) is a recently defined inflammatory central nervous system (CNS) …